Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients.
Chemotherapy induced liver injury
Liver Steatosis
Liver metastases
Rectal Cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Mar 2021
09 Mar 2021
Historique:
received:
05
11
2020
accepted:
24
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
11
5
2021
Statut:
epublish
Résumé
The liver is one of the most frequent sites of metastases in rectal cancer. This study aimed to evaluate how the development of synchronous or metachronous liver metastasis and overall survival are impacted by baseline liver steatosis and chemotherapy-induced liver damage in rectal cancer patients. Patients diagnosed with stage II to IV rectal cancer between 2010 and 2016 in our province with suitable baseline CT scan were included. Data on cancer diagnosis, staging, therapy, outcomes and liver function were collected. CT scans were retrospectively reviewed to assess baseline steatosis (liver density < 48 HU and/or liver-to-spleen ratio < 1.1). Among patients without baseline steatosis and treated with neoadjuvant chemotherapy, chemotherapy-induced liver damage was defined as steatosis appearance, ≥ 10% liver volume increase, or significant increase in liver function tests. We included 283 stage II to IV rectal cancer patients with suitable CT scan (41% females; mean age 68 ± 14 years). Steatosis was present at baseline in 90 (31.8%) patients, synchronous liver metastasis in 42 (15%) patients and metachronous liver metastasis in 26 (11%); 152 (54%) deaths were registered. The prevalence of synchronous liver metastasis was higher in patients with steatosis (19% vs 13%), while the incidence of metachronous liver metastasis was similar. After correcting for age, sex, stage, and year of diagnosis, steatosis was not associated with metachronous liver metastasis nor with overall survival. In a small analysis of 63 patients without baseline steatosis and treated with neoadjuvant chemotherapy, chemotherapy-induced liver damage was associated with higher incidence of metachronous liver metastasis and worse survival, results which need to be confirmed by larger studies. Our data suggest that rectal cancer patients with steatosis had a similar occurrence of metastases during follow-up, even if the burden of liver metastases at diagnosis was slightly higher, compatible with chance.
Sections du résumé
BACKGROUND
BACKGROUND
The liver is one of the most frequent sites of metastases in rectal cancer. This study aimed to evaluate how the development of synchronous or metachronous liver metastasis and overall survival are impacted by baseline liver steatosis and chemotherapy-induced liver damage in rectal cancer patients.
METHODS
METHODS
Patients diagnosed with stage II to IV rectal cancer between 2010 and 2016 in our province with suitable baseline CT scan were included. Data on cancer diagnosis, staging, therapy, outcomes and liver function were collected. CT scans were retrospectively reviewed to assess baseline steatosis (liver density < 48 HU and/or liver-to-spleen ratio < 1.1). Among patients without baseline steatosis and treated with neoadjuvant chemotherapy, chemotherapy-induced liver damage was defined as steatosis appearance, ≥ 10% liver volume increase, or significant increase in liver function tests.
RESULTS
RESULTS
We included 283 stage II to IV rectal cancer patients with suitable CT scan (41% females; mean age 68 ± 14 years). Steatosis was present at baseline in 90 (31.8%) patients, synchronous liver metastasis in 42 (15%) patients and metachronous liver metastasis in 26 (11%); 152 (54%) deaths were registered. The prevalence of synchronous liver metastasis was higher in patients with steatosis (19% vs 13%), while the incidence of metachronous liver metastasis was similar. After correcting for age, sex, stage, and year of diagnosis, steatosis was not associated with metachronous liver metastasis nor with overall survival. In a small analysis of 63 patients without baseline steatosis and treated with neoadjuvant chemotherapy, chemotherapy-induced liver damage was associated with higher incidence of metachronous liver metastasis and worse survival, results which need to be confirmed by larger studies.
CONCLUSIONS
CONCLUSIONS
Our data suggest that rectal cancer patients with steatosis had a similar occurrence of metastases during follow-up, even if the burden of liver metastases at diagnosis was slightly higher, compatible with chance.
Identifiants
pubmed: 33750342
doi: 10.1186/s12885-021-07980-9
pii: 10.1186/s12885-021-07980-9
pmc: PMC7941741
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Références
Minerva Chir. 2005 Jun;60(3):185-90
pubmed: 15985994
Clin Liver Dis. 2018 Feb;22(1):93-108
pubmed: 29128063
Int J Colorectal Dis. 2013 Aug;28(8):1065-72
pubmed: 23392476
J Surg Res. 2015 Apr;194(2):496-504
pubmed: 25528682
J Hepatol. 2017 Jul;67(1):84-91
pubmed: 28284915
Br J Surg. 2013 May;100(6):820-6
pubmed: 23354994
Ann Surg. 2013 Nov;258(5):731-40; discussion 741-2
pubmed: 24045448
Int J Cancer. 2015 Feb 15;136(4):E3-13
pubmed: 25053237
Ann Surg Oncol. 2012 Dec;19(13):4287-99
pubmed: 22766981
Radiology. 2007 Aug;244(2):479-85
pubmed: 17641368
Dis Colon Rectum. 2007 Nov;50(11):1783-99
pubmed: 17874269
AJR Am J Roentgenol. 2019 Apr;212(4):782-787
pubmed: 30779660
Eur Radiol. 2019 Aug;29(8):4427-4435
pubmed: 30569183
HPB (Oxford). 2016 Apr;18(4):389-96
pubmed: 27037210
Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):224-38
pubmed: 21386810
PeerJ. 2019 Mar 14;7:e6612
pubmed: 30886784
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur J Intern Med. 2016 Oct;34:89-93
pubmed: 27545645
Oncotarget. 2015 Nov 17;6(36):38658-66
pubmed: 26484417
Recent Results Cancer Res. 2005;165:221-30
pubmed: 15865037
Int J Cancer. 2019 Jul 1;145(1):110-121
pubmed: 30585621
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
World J Surg. 2018 Aug;42(8):2642-2650
pubmed: 29352337
Breast Cancer Res Treat. 2017 Nov;166(1):289-297
pubmed: 28741275
Hepatogastroenterology. 1997 Jul-Aug;44(16):1069-75
pubmed: 9261601
J Clin Oncol. 2006 May 1;24(13):2065-72
pubmed: 16648507
Lancet Oncol. 2009 Mar;10(3):278-86
pubmed: 19261256
Cancer. 2002 Mar 15;94(6):1642-7
pubmed: 11920523
Cell Stem Cell. 2015 Jul 2;17(1):47-59
pubmed: 26140605